DK1562604T3 - Prostaglandinforbindelser til behandling af fedme - Google Patents

Prostaglandinforbindelser til behandling af fedme

Info

Publication number
DK1562604T3
DK1562604T3 DK03758747.4T DK03758747T DK1562604T3 DK 1562604 T3 DK1562604 T3 DK 1562604T3 DK 03758747 T DK03758747 T DK 03758747T DK 1562604 T3 DK1562604 T3 DK 1562604T3
Authority
DK
Denmark
Prior art keywords
obesity
treatment
prostaglandin compounds
prostaglandin
compounds
Prior art date
Application number
DK03758747.4T
Other languages
Danish (da)
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of DK1562604T3 publication Critical patent/DK1562604T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03758747.4T 2002-10-23 2003-10-22 Prostaglandinforbindelser til behandling af fedme DK1562604T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42033602P 2002-10-23 2002-10-23
PCT/JP2003/013453 WO2004037268A1 (en) 2002-10-23 2003-10-22 Prostaglandin compounds for the treatment of obesity

Publications (1)

Publication Number Publication Date
DK1562604T3 true DK1562604T3 (da) 2012-04-02

Family

ID=32176556

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03758747.4T DK1562604T3 (da) 2002-10-23 2003-10-22 Prostaglandinforbindelser til behandling af fedme

Country Status (11)

Country Link
US (1) US8114911B2 (cg-RX-API-DMAC7.html)
EP (1) EP1562604B1 (cg-RX-API-DMAC7.html)
JP (1) JP4705782B2 (cg-RX-API-DMAC7.html)
AT (1) ATE539756T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003274735B2 (cg-RX-API-DMAC7.html)
CA (1) CA2502439C (cg-RX-API-DMAC7.html)
DK (1) DK1562604T3 (cg-RX-API-DMAC7.html)
ES (1) ES2379652T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ539582A (cg-RX-API-DMAC7.html)
PT (1) PT1562604E (cg-RX-API-DMAC7.html)
WO (1) WO2004037268A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641462B1 (en) 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
CA2681668C (en) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
AU2013347949A1 (en) 2012-11-21 2015-06-11 Velakine Therapeutics, Inc. Methods and compositions for locally increasing body fat
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
ES2785382T3 (es) 2013-04-12 2020-10-06 Allergan Inc Liberación sostenida de bimatoprost, análogos de bimatoprost, prostamidas y prostaglandinas para la reducción de grasa
NO2753788T3 (cg-RX-API-DMAC7.html) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
US11452703B2 (en) 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US388919A (en) * 1888-09-04 Benjamin scables
US3888919A (en) * 1971-03-11 1975-06-10 Upjohn Co 11,15 dimethyl pge' 1 'and pgf' 1'
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
NZ226199A (en) * 1988-09-15 1991-05-28 Ueno Seiyaku Oyo Kenkyujo Kk 13,14-dihydro-15-keto-pgf derivatives and pharmaceutical compositions
NZ226198A (en) * 1988-09-15 1991-05-28 Ueno Seiyaku Oyo Kenkyujo Kk Fervescence (temperature raising) composition comprising 15-keto-pge
JPH085794B2 (ja) * 1989-07-27 1996-01-24 株式会社上野製薬応用研究所 高脂質血症処置・血中脂質成分低下剤
DE69006964T2 (de) * 1989-07-27 1994-06-09 Ueno Seiyaku Oyo Kenkyujo Kk Behandlung von Hyperlipidemia mit 15-keto-Prostaglandin-Verbindungen.
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
TW249226B (cg-RX-API-DMAC7.html) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
DE69900847T2 (de) * 1998-04-17 2002-09-12 Tufts College Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
JP2000157260A (ja) * 1998-11-26 2000-06-13 Toyobo Co Ltd 初代前駆脂肪細胞の分化誘導方法及びその分化用培地
JP4332316B2 (ja) 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
PT1389116E (pt) 2001-05-18 2008-04-11 Sucampo Ag Composição de indução catártica
BR0212233A (pt) 2001-08-31 2004-10-05 Sucampo Ag Abridor de canal de cloreto
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
KR101164838B1 (ko) 2002-12-27 2012-07-11 수캄포 아게 복부 불쾌감 치료용 프로스타글랜딘의 유도체
EP1641462B1 (en) 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
ES2371658T3 (es) 2005-04-12 2012-01-05 Sucampo Ag Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales.

Also Published As

Publication number Publication date
EP1562604B1 (en) 2012-01-04
ES2379652T3 (es) 2012-04-30
EP1562604A1 (en) 2005-08-17
JP4705782B2 (ja) 2011-06-22
NZ539582A (en) 2007-07-27
PT1562604E (pt) 2012-04-09
WO2004037268A1 (en) 2004-05-06
US20050261373A1 (en) 2005-11-24
US8114911B2 (en) 2012-02-14
JP2006506381A (ja) 2006-02-23
ATE539756T1 (de) 2012-01-15
AU2003274735A1 (en) 2004-05-13
CA2502439A1 (en) 2004-05-06
CA2502439C (en) 2011-11-22
AU2003274735B2 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
CY1113362T1 (el) Διαρυλ-αιθερες, ως ανταγωνιστης οπιοειδους υποδοχεως
UY28290A1 (es) Compuestos farmacéuticos novedosos
UY28014A1 (es) Compuestos quimicos
ECSP055913A (es) Inhibidores de las polimerasas víricas
DE60317884D1 (de) Natriumkanalblocker
SE0100903D0 (sv) Compounds
DK1385515T3 (da) Spiropyrazole forbindelser
ECSP056220A (es) Nuevos compuestos 2-piridiniletilbenzamida
DK1562604T3 (da) Prostaglandinforbindelser til behandling af fedme
ATE411287T1 (de) Neue metallproteinaseinhibitoren
EA200601295A1 (ru) Производные 1,3-диоксана и их аналоги, применимые для лечения i.a. ожирения и диабета
EA200600330A1 (ru) Замещённые имидазопиримидины для предупреждения и лечения рака
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DK1511472T3 (da) Anvendelige forbindelser til behandling af Anthrax og hæmning af letalfaktor
ATE443044T1 (de) Tace inhibitoren
WO2004030664A3 (en) New compounds for the inhibition of undesired cell proliferation and use thereof
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
MA27549A1 (fr) N-sulfonyl-4-methylene-amino-3-hydroxy-2-pyridones
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
DK1301475T3 (da) Arylsulfonamider, som serotoninantagonist til behandling af obesitet
BR0214445B1 (pt) processos para a produção de compostos.
ATE372982T1 (de) 2-(3-sulfonylamino-2-oxopyrrolidin-1- yl)propanamide als factor xa inhibitoren